Edesa Biotech
EDSA
20 hedge funds and large institutions have $6.89M invested in Edesa Biotech in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
1,867% more capital invested
Capital invested by funds: $350K → $6.89M (+$6.54M)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
34.4% more ownership
Funds ownership: 5.98% → 40.38% (+34%)
18% more funds holding
Funds holding: 17 → 20 (+3)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.48M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.48M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$1.48M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.35M |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
-$185K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$52.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$25.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.84K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$58 |
EDSA Hedge Fund Activity: Q1 2025 in Review
20 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q1 2025, worth a combined $6.89M — up 1,867% from $350K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new EDSA positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $1.48M. The largest seller was CM Management, exiting entirely with an estimated $185K sold.
- 20 institutional investors held Edesa Biotech (EDSA) as of Q1 2025, up from 17 in Q4 2024.
- Funds reported $6.89M of Edesa Biotech stock for Q1 2025, up 1,867% quarter-over-quarter.
- 7 funds opened new Edesa Biotech positions in Q1 2025 and 3 closed out, a net change of +4 holders.
- The largest Edesa Biotech buyer in Q1 2025 was Rubric Capital Management (New York), an estimated $1.48M added.
- The largest Edesa Biotech seller in Q1 2025 was CM Management, an estimated $185K sold.
Based on aggregated 13F filings for Q1 2025.